Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |
PMID | |
Authors | AE. Drilon, V Subbiah, GR. Oxnard, TM Bauer, V Velcheti, NJ. Lakhani, B Besse, K Park, JD. Patel, ME. Cabanillas, ML Johnson, KL. Reckamp, V Boni, HHF. Loong, M Schlumberger, B Solomon, S Cruickshank, SM. Rothenberg, MH. Shah, LJ. Wirth |
Title | A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with RET-altered cancers. |
Journal | J Clin Oncol |
Vol | |
Issue | |
Date | |
URL | https://meetinglibrary.asco.org/record/161573/abstract |
Abstract Text | J Clin Oncol 36, 2018 (suppl; abstr 102) |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
RET fusion | thyroid gland papillary carcinoma | sensitive | Selpercatinib | Phase I | Actionable | In a Phase I trial, Retevmo (selpercatinib) treatment resulted in an objective response rate of 83% (5/6) in RET fusion-positive papillary thyroid cancer patients (J Clin Oncol 36, 2018 (suppl; abstr 102); NCT03157128). | detail... |
RET V804M | thyroid gland medullary carcinoma | sensitive | Selpercatinib | Phase I | Actionable | In a Phase I trial, Retevmo (selpercatinib) treatment resulted in partial response in a thyroid medullary cancer patient harboring RET V804M (J Clin Oncol 36, 2018 (suppl; abstr 102); NCT03157128). | detail... |